BiondVax Pharmaceuticals Ltd. Announces Closing of U.S. Initial Public Offering
May 15 2015 - 11:13AM
BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV) (Nasdaq:BVXVW), a
clinical stage biopharmaceutical company focused on developing and
commercializing immunomodulation therapies for infectious diseases,
today announced the closing of its previously announced U.S.
initial public offering of 1,910,000 American Depositary Shares
(ADSs), each ADS representing 40 of its ordinary shares, and
warrants to purchase up to an aggregate of 1,910,000 ADSs at an
offering price of $5.00 per ADS and $0.01 per warrant. In addition,
the underwriter has partially exercised their option to purchase an
additional 128,000 warrants to purchase 128,000 ADSs. The warrants
have a per ADS exercise price of $6.25, are exercisable immediately
and will expire on May 15, 2020. Gross proceeds to BiondVax from
this offering are approximately $9.57 million before deducting
underwriting discounts and commissions and other estimated offering
expenses payable by BiondVax.
Aegis Capital Corp. acted as the sole book-running manager for
the offering.
A registration statement relating to these securities has been
declared effective by the Securities and Exchange Commission on May
11, 2015.
A final prospectus relating to the offering has been filed
with the SEC and is available on the SEC's web site at
http://www.sec.gov. Copies of the final prospectus relating to the
offering may be obtained from the offices of Aegis Capital Corp.,
Prospectus Department, 810 Seventh Avenue, 18th Floor, New York,
NY, 10019, telephone: 212-813-1010 or email:
prospectus@aegiscap.com, or from the above-mentioned SEC
website.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About BiondVax
BiondVax is an innovative biopharmaceutical company developing a
universal flu vaccine, designed to provide multi-season and
multi-strain protection against most human influenza virus strains,
including both seasonal and pandemic flu strains.
BiondVax's technology utilizes a unique, proprietary combination
of conserved and common peptides from influenza virus proteins to
activate both arms of the immune system for a cross-protecting and
long-lasting effect. Forward Looking
Statements
This press release contains forward-looking statements. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements involve certain risks and uncertainties, including,
among others, risks impacting the ability of BiondVax
Pharmaceuticals Ltd. to complete any public offering of its
securities because of general market conditions or other factors
and risks that could cause the results to differ materially from
those expected by the management of BiondVax Pharmaceuticals
Ltd. More detailed information about the risks and
uncertainties affecting BiondVax Pharmaceuticals Ltd. is
contained under the heading "Risk Factors" in BiondVax
Pharmaceuticals Ltd.'s registration statement on Form F-1
filed with the SEC, which is available on
the SEC's web site, www.sec.gov. BiondVax
Pharmaceuticals Ltd. undertakes no obligation to update or
revise any forward-looking statements.
CONTACT: Company Contact
Ron Babecoff, CEO
babecoff@biondvax.com
Investor Relations Contact
GK Investor Relations
Kenny Green, Partner
1 646 201 9246
biondvax@gkir.com
BiondVax Pharmaceuticals (NASDAQ:BVXVW)
Historical Stock Chart
From May 2024 to Jun 2024
BiondVax Pharmaceuticals (NASDAQ:BVXVW)
Historical Stock Chart
From Jun 2023 to Jun 2024